Pentosan polysulfate - Urigen Pharmaceuticals
Alternative Names: URG 501Latest Information Update: 22 Sep 2023
At a glance
- Originator Urigen Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Antiallergics; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
- Mechanism of Action Cell membrane permeability inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Interstitial cystitis
Most Recent Events
- 22 Sep 2023 Preclinical development in interstitial cystitis is underway in USA (Urigen Pharmaceuticals pipeline, September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Interstitial-cystitis in USA (Intraperitoneal)
- 07 Oct 2016 Preclinical trials in Interstitial cystitis in USA (Intraperitoneal) before October 2016 (Urigen Pharmaceuticals pipeline, October 2016)